ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.430,05
1,42%
S&P 500
5.183,73
0,06%
Dow Jones
38.862,47
0,03%
Euro vs US Dollar
1,07545
-0,12%
Bitcoin
63.220,00
0,08%
Registration Strip Icon for monitor Überwachen Sie mehrere Echtzeitkurse von führenden Börsen wie NASDAQ, NYSE, AMEX, Bovespa und mehr.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Enanta Pharmaceuticals Inc (ENTA)

  7. Enanta Pharmaceuticals Inc (ENTA) News

ENTA Enanta Pharmaceuticals Inc

13,14
-1,46 (-10,00%)
Zuletzt aktualisiert: 20:04:53
Verzögert um 15 Minuten
Name Symbol Markt Aktientyp
Enanta Pharmaceuticals Inc ENTA NASDAQ Common Stock
  Änderung Änderung % Aktuell Zeit
Upgrade Icon
-1,46 -10,00% 13,14 20:04:53
Handelsbeginn Niedrig Hoch Schlusskurs Handelsende
11,60 11,60 13,21 14,60
more quote information »

Aktuelle News

Datum Zeit Quelle Überschrift
07.5.202413:00BWEnanta Pharmaceuticals to Participate at the JMP Securities..
06.5.202422:05EDGAR2Form 8-K - Current report
06.5.202422:01BWEnanta Pharmaceuticals Reports Financial Results for its..
30.4.202413:10BWEnanta Pharmaceuticals Announces Inducement Grants Under..
30.4.202413:00BWEnanta Pharmaceuticals Announces the Appointment of Matthew..
29.4.202413:00BWEnanta Pharmaceuticals to Host Conference Call on May 6 at..
17.4.202413:00BWEnanta Pharmaceuticals Announces Data Presentation at ESCMID..
08.3.202423:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08.3.202423:27EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08.3.202423:23EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08.3.202423:19EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08.3.202423:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08.3.202423:12EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06.3.202413:00BWEnanta Pharmaceuticals to Participate at Leerink Partners..
28.2.202400:31EDGAR2Form 4 - Statement of changes in beneficial ownership of..
27.2.202419:11EDGAR2Form SCHEDULE 13G - Statement of acquisition of beneficial..
15.2.202402:23EDGAR2Form 4 - Statement of changes in beneficial ownership of..
15.2.202402:21EDGAR2Form 4 - Statement of changes in beneficial ownership of..
15.2.202402:18EDGAR2Form 4 - Statement of changes in beneficial ownership of..
15.2.202402:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
15.2.202402:12EDGAR2Form 4 - Statement of changes in beneficial ownership of..
15.2.202402:09EDGAR2Form 4 - Statement of changes in beneficial ownership of..
15.2.202402:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14.2.202420:26EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
08.2.202422:24EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
07.2.202422:05EDGAR2Form 8-K - Current report
07.2.202422:01BWEnanta Pharmaceuticals Reports Financial Results for its..
06.2.202413:00BWEnanta Pharmaceuticals to Participate at the Oppenheimer..
31.1.202413:00BWEnanta Pharmaceuticals to Host Conference Call on February 7..
26.1.202422:37EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
26.1.202422:25EDGAR2Form DEF 14A - Other definitive proxy statements
24.1.202423:23EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
11.1.202422:15EDGAR2Form SC 13G - Statement of acquisition of beneficial..
04.1.202413:00BWEnanta Pharmaceuticals to Provide Updates on its Research..
03.1.202413:00BWEnanta Pharmaceuticals to Present at the 42nd Annual J.P...
26.12.202322:06EDGAR2Form 8-K - Current report
16.12.202302:08EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12.12.202323:16EDGAR2Form 144 - Report of proposed sale of securities
07.12.202302:31EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07.12.202302:29EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07.12.202302:26EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07.12.202302:24EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07.12.202302:22EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07.12.202302:19EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07.12.202302:17EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06.12.202303:24EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06.12.202303:21EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06.12.202303:19EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06.12.202303:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06.12.202303:11EDGAR2Form 4 - Statement of changes in beneficial ownership of..

Kürzlich von Ihnen besucht

NASDAQ
ENTA
Enanta Pharmaceuticals
Delayed Upgrade Clock
ADVFN Logo

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten